Clonal myelodysplastic cells present in apheresis product before transplantation.
Amigo
M L
ML
del Cañizo
M C
MC
Hernández
J M
JM
Gonzalez
M B
MB
Gutiérrez
N
N
Mateos
M V
MV
San Miguel
J F
JF
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002330:Carmustine / Q000008:administration & dosage; D002869:Chromosome Aberrations / Q000235:genetics*; D002884:Chromosomes, Human, Pair 15 / Q000235:genetics; D002897:Chromosomes, Human, Pair 7 / Q000235:genetics; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D019650:Hematopoietic Stem Cell Mobilization / Q000009:adverse effects; D006412:Hematopoietic Stem Cells; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007621:Karyotyping; D016393:Lymphoma, B-Cell / Q000235:genetics* / Q000628:therapy; D008224:Lymphoma, Follicular / Q000235:genetics* / Q000628:therapy; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D011034:Podophyllotoxin / Q000008:administration & dosage; D012189:Retrospective Studies
D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D003520:Cyclophosphamide; D011034:Podophyllotoxin; D008558:Melphalan; D002330:Carmustine